Summary of the safety profile: The most frequent of adverse reactions reported are fatigue (1.2 %), dry mouth (0.8 %) and headache (0.6 %).
Paediatric population: In 12 through 17 years of age, the most common adverse event was headache; this occurred in 5.9 % of patients treated with desloratadine.
Tabulated list of adverse reactions: The adverse reactions reported in excess of placebo and other undesirable effects reported during the post-marketing period are listed in the following table. Frequencies are defined as very common, common, uncommon, rare, very rare and not known (cannot be estimated from the available data). (See table.)
Click on icon to see table/diagram/image